COLL News and Press, Collegium Pharmaceutical Inc. From 01/28/23

Summary Collegium Pharmaceutical has caught a strong bid since bouncing off 52-week lows last October. A number of catalysts have driven the stock up the page and shares now trade at multi-year highs. The company projects strong growth prospects in FY23. Delving deeper into the ...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million – – Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million – – Adjusted EBITDA* Expected in the Range of $355.0 Million to $370.0 ...

STOUGHTON, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Federal Circuit has upheld the judgment of the U.S. District Court for the District of Delaware that certain claims ...

STOUGHTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in a fireside chat at the Piper Sandler 34 th Annual Healthcare Conference bei...

Summary My Collegium Pharmaceutical position has been gathering thanks to the ticker trading between my Buy and Sell Targets. The company's Q3 earnings beat has forced me to update my strategy. Collegium's new products from the BDSI acquisition have already helped the company repo...

Collegium Pharmaceutical, Inc. (COLL) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Dawn Schottlandt - Managing Director-Argot Partners Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott...

The following slide deck was published by Collegium Pharmaceutical, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Collegium Pharmaceutical, Inc. 2022 Q2 - Results - Earnings Call Presentation

Collegium Pharmaceutical press release ( NASDAQ: COLL ): Q3 GAAP EPS of $0.01 beats by $0.15 . Revenue of $127M (+61.1% Y/Y) beats by $2.64M . Updated Full Year 2022 Guidance : Total Product Revenues seen at $455M to $465M, prior outlook $450M to $4...

– Generated Record Net Revenue of $127.0 Million – – Completed Xtampza ® ER Contract Renegotiations, Confirmed Xtampza ER Gross-To-Net Will be Less Than 65% Beginning January 2023 – – Returned $10M in Capital to Shareholder...